<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611311</url>
  </required_header>
  <id_info>
    <org_study_id>1289.17</org_study_id>
    <secondary_id>2012-000052-34</secondary_id>
    <nct_id>NCT01611311</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306 Film-coated Tablets Given Orally q.d. for 14 Days in Young and Elderly Healthy Male/Female Volunteers (Randomized, Double-blind, Placebo Controlled Within Dose Groups Phase I Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of the current study is to investigate the safety and tolerability of
      BI 409306 in healthy young and elderly male and female volunteers following oral
      administration of repeated rising doses, given once daily over 14 days to young healthy
      genotyped and elderly healthy male/female volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 11 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically relevant findings in physical examination</measure>
    <time_frame>Up to 11 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant abnormalities in electrocardiogram (ECG) results</measure>
    <time_frame>Up to 11 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with significant changes from baseline laboratory measurements</measure>
    <time_frame>Up to 11 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of tolerability by investigator (global assessment)</measure>
    <time_frame>Up to 11 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicidality assessment</measure>
    <time_frame>Up to 11 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Color discrimination test</measure>
    <time_frame>Up to 11 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual acuity test</measure>
    <time_frame>Up to 11 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically relevant findings in Vital signs (blood pressure, pulse rate, orthostasis test)</measure>
    <time_frame>Up to 34 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>Up to 11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>Up to 11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to 24 hours)</measure>
    <time_frame>Up to 11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss (maximum measured concentration of the analyte in plasma at steady state)</measure>
    <time_frame>Up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss (time from last dosing to Cmax,ss)</measure>
    <time_frame>Up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)</measure>
    <time_frame>Up to 17 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 409306 BS medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Film-coated tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 409306 BS high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Film-coated tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Film-coated tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306 BS</intervention_name>
    <description>Medium dose film-coated tablet</description>
    <arm_group_label>BI 409306 BS medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306 BS</intervention_name>
    <description>High dose film-coated tablet</description>
    <arm_group_label>BI 409306 BS high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. Healthy male/female subjects

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1289.17.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2012</study_first_submitted>
  <study_first_submitted_qc>May 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2012</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

